2,208 on NobleID · 212 being added
| Title | Cited by | Year |
|---|---|---|
| 4,742 | 2014 | |
Pembrolizumab for Early Triple-Negative Breast Cancer New England Journal of Medicine | 3,227 | 2020 |
| 2,649 | 2012 | |
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer New England Journal of Medicine | 2,625 | 2018 |
| 2,142 | 2017 |
Creating an account is free.
For data access, contact info@nobleid.org.